Searched for
WCK 771
How Wockhardt Chairman Habil Khorakiwala plans to pull the company out of trouble45 years after he made a profound statement about dying only once, the chairman of Wockhardt would like to repeat it to investors, regulato...- Drug maker Wockhardt on fast track of innovationThe renewed optimism in the global outlook for anti-infective products vindicates the company’s long-term strategy.
- Wockhardt gets QIDP status for pneumonia drug from USFDAWockhardt today said a product from its new drug discovery programme, which aims to treat pneumonia, has received QIDP status from the US h...
- Wockhardt Ltd rallies on receiving QIDP status for two drugsThis is the first instance of an Indian pharmaceutical company receiving a QIDP status, Wockhardt said in a release issued.
- Nifty breaches 8,000-mark for first time, Sensex hits new peak; top 15 stocksThe 50-share NSE Nifty index breached the 8,000-mark for the first time ever in trade on Monday and BSE Sensex logged a new peak of 26,854....
- Fifteen stocks in focus in Monday morning tradeThe 50-share Nifty index surged over 40 points to hit its fresh record high of 8,007.95, led by gains in NTPC, Coal India, Hindalco, L&T an...
- Wockhardt's WCK 771 and WCK 2349 recieve QIDP status from US FDAThis is the first instance of an Indian pharmaceutical company receiving a QIDP status, Wockhardt said in a release issued here.
- USFDA grants Qualified Infectious Disease Product status to two Wockhardt drugsTwo drugs - WCK 771 and WCK 2349 - have received QIDP status, which allows fast-track review of the drug application by the USFDA.
- Wockhardt to spin off R&D businessDrug maker Wockhardt said on Friday it will spin off its R&D business and list the new company on stock exchange on January 1, 2009.
- Wockhardt to hive off innovative R&D businessWockhardt planning to spin off its innovative R and D business into a separate co. The move is being contemplated to seek funding support f...
- Indian pharma cos close to blockbuster breakthroughIndian pharma majors may manage to market their first indi-genous "blockbuster drugs" or new chemical entities (NCEs) in the next four year...
- Wockhardt in talks to out-license research moleculesWockhardt is likely to out-license some of its research molecules to global pharma companies.
Load More
